Trou­bled Teva's suc­ces­sor to Co­pax­one just failed a big PhI­II test for mul­ti­ple scle­ro­sis

Copy­right (c) Flash 90 2013

Af­ter years of set­backs, de­lays and sundry frus­tra­tions, a deeply trou­bled Te­va says that a late-stage tri­al for laquin­i­mod — long billed as a suc­ces­sor to the ag­ing flag­ship ther­a­py Co­pax­one for mul­ti­ple scle­ro­sis — failed the test on the re­laps­ing-re­mit­ting form of the dis­ease.

Te­va’s drug — her­ald­ed as its bright­est pipeline prospect — did not meet the pri­ma­ry end­point, try­ing to sig­nif­i­cant­ly im­prove the time to dis­abil­i­ty pro­gres­sion com­pared to place­bo af­ter three months.

Michael Hay­den, Te­va

In­ves­ti­ga­tors are still test­ing this drug for pri­ma­ry pro­gres­sive MS and Hunt­ing­ton’s dis­ease, but with the lat­est sting­ing fail­ure, it’s un­like­ly that an­a­lysts will as­cribe much po­ten­tial val­ue to the drug. At the be­gin­ning of 2016 Te­va — part­nered with Ac­tive Biotech — was forced to sus­pend use of the high­est dose of laquin­i­mod due to car­dio side ef­fects. Nev­er­the­less, the com­pa­ny was pre­dict­ing that it could win with low­er dos­es and prep for a launch af­ter com­plet­ing stud­ies this year.

Shares of Ac­tive {$AC­TI: STO} dropped 66% on the news.

In the mean­time, with gener­ic com­pe­ti­tion loom­ing for Co­pax­one, Roche re­cent­ly won an ap­proval for Ocre­vus as a new ther­a­py for both re­laps­ing-re­mit­ting and pri­ma­ry pro­gres­sive MS, look­ing to dis­rupt a mar­ket in which Bio­gen is see­ing rev­enue be­gin to wane for Tec­fidera.

Te­va, though, is in a jam. Last year the com­pa­ny bought Al­ler­gan’s big gener­ics port­fo­lio just as gener­ic drug prices were be­gin­ning to erode. That trig­gered a move to re­or­ga­nize and cut costs, which is still just be­gin­ning. Now the com­pa­ny, which had tried to con­tin­ue to de­vel­op brand­ed drugs while al­so pur­su­ing the gener­ics mar­ket, finds it­self with lim­it­ed prospects in the clin­ic to ex­cite an­a­lysts — if that’s still pos­si­ble.

In ear­ly April Te­va did win an ap­proval for Auste­do to treat Hunt­ing­ton’s chorea, a drug they bought two years ago with ex­pec­ta­tions of a quick OK. Last fall Te­va in­cit­ed a con­sid­er­able amount of spec­u­la­tion about how it could one day ri­val Neu­ro­crine in tar­dive dysk­i­ne­sia with Auste­do. But their mixed re­sults al­so sparked more than a lit­tle kick­back from an­a­lysts who pre­fer In­grez­za. The FDA hand­ed Te­va’s drug — ac­quired 2 years ago in a $3.5 bil­lion Aus­pex buy­out — as­signed them an Au­gust 30 PDU­FA date.

In the ab­sence of a game plan, Te­va is stick­ing with op­ti­mism in the face of de­feat, putting the best face on an ug­ly fail­ure.

“We have learned a great deal from the CON­CER­TO tri­al and we will con­tin­ue our analy­sis of the da­ta,” said Michael Hay­den, Pres­i­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va. “Al­though we are dis­ap­point­ed by not meet­ing the pri­ma­ry end­point, we did see pos­i­tive re­sults on a num­ber of sec­ondary and ex­plorato­ry end­points which fu­els our be­lief in the po­ten­tial of laquin­i­mod as a pos­si­ble treat­ment for neu­rode­gen­er­a­tive dis­eases. While we have no cur­rent plans to fur­ther pur­sue laquin­i­mod in RRMS, we are con­tin­u­ing to study it in two oth­er tri­als.”

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bargain, AstraZeneca is already on a short path to scooping up a cutting-edge win with a likely approval for their SGLT2 drug Farxiga in cutting the risk of heart failure. Now the pharma giant says it can point to solid evidence that the drug — initially restricted to diabetes — also works for chronic kidney disease, potentially adding a blockbuster indication for the franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

It is 'kind of a proven tech­nol­o­gy': Hep B vac­cine mak­er joins glob­al hunt for coro­n­avirus vac­cine

Using lab-grown proteins that are engineered to mimic the architecture of viruses to induce an immune response, VBI Vaccines is joining the hunt for a coronavirus vaccine — harnessing technology that has initially been proved safe in early trials as a prophylactic for cytomegalovirus (CMV) infection.

Unlike the raft of the companies in the Covid-19 vaccine race — including Moderna, CureVac and J&J — VBI is taking a pan-coronavirus approach, by developing a vaccine that will encompass Covid-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS).

Can a pair of top AveX­is alum­ni steer a new gene ther­a­py up­start to R&D glo­ry? 3 VCs bet $60M on it

VCs love few things more than a proven executive team when it comes to launching a new company. And now a group of A-listers has turned to a pair of top execs out of AveXis to steer the latest gene therapy player into the clinic.

The biotech is Waltham, MA-based Affinia and the two execs are Sean Nolan and Rick Modi — the former CEO and CBO respectively of AveXis, the gene therapy pioneer that fetched $8.7 billion in a sale to Novartis. Nolan has now taken the chairman’s role at Affinia while Modi moves up to the CEO post at the company.

Un­de­terred by a pan­dem­ic, Gilde Health­care rais­es their largest fund yet

When Pieter van der Meer started raising the capital for Gilde Healthcare’s fifth fund in the waning months of 2019, he had his eyes on a different chain of events that could change the healthcare system and perhaps even play to his firm’s advantage: The US presidential election.

Since raising their third fund in 2011, the 34-year-old Dutch firm had focused on value-based care. They chose late-stage biotechs that came up with new devices and delivery systems for de-risked established compounds, and when they chose preclinical biotechs, they spoke with potential pharma partners, payers and regulators to ask where and at what prices the drug made sense. As the Democratic primary became a contest over how to lower healthcare costs, it looked like a strategy that could pay off.

Daniel O'Day (AP Images)

Gilead CEO Dan O'­Day of­fers a de­tailed ex­pla­na­tion on remde­sivir ac­cess — re­as­sur­ing an­a­lysts that Covid-19 da­ta are com­ing fast

After coming under heavy fire from consumer groups ready to pummel them for grabbing the FDA’s orphan status for remdesivir — reserved to encourage the development of rare disease therapies — Gilead CEO Daniel O’Day had some explaining to do about the company’s approach to providing access to this drug to patients suffering from Covid-19. And he set aside time over the weekend to patiently explain how they are making their potential pandemic drug available in a new program — one he feels can better be used to address a growing pack of infected patients desperately seeking remdesivir under compassionate use provisions.

In addition to trying to reassure patients that they will once again have an avenue to pursue access, O’Day also reassured some analysts who had been fretting that China’s quick comeback from the coronavirus outbreak could derail its ultra-fast schedule for testing the drug in patients. The data are still expected in a few weeks, he says in the letter, putting the readout in April.

O’Day emphasizes that Gilead intends to pursue a pricing approach that will make this drug widely available — if it proves effective and safe. But no one is quite sure just what the longterm value would be, given the work being done on a variety of vaccines that may be rolled out as early as this fall — at least to the most heavily threatened groups.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: J&J, BAR­DA set ear­ly 2021 fin­ish line for $1B vac­cine race; FDA al­lows emer­gency drug use, ahead of piv­otal da­ta

J&J has zeroed in on a Covid-19 vaccine candidate that it hopes to begin testing in humans by September this year — with the extraordinary goal of getting it ready for emergency use in early 2021. And together with BARDA, it’s committing $1 billion to make it happen.

That kind of accelerated timeline would fall on the fast side of NIAID director Anthony Fauci’s well-publicized prediction that it would be another 12 to 18 months before a vaccine can be available for public use. A Phase I trial of Moderna’s mRNA vaccine began two weeks ago, and both the biotech and fellow mRNA player CureVac have discussed similar, if not even faster, timelines for emergency use among healthcare workers.